Ｏｂｊｅｃｔｉｖｅ　The aim of this study was to assess the prevention profiles of parecoxib on catheter-related bladder discomfort (CRBD) after transurethral resection of bladder tumor(TURBT).　Methods　Fifty-six male adult patients undergoing transurethral resection of bladder tumor were enrolled. Induction and maintenance of anesthesia were standardized. Patients were randomly divided into two groups according to the random number table method that received either intravenous 0.9% NaCl solution [control group (group C)] or parecoxib (40 mg) (group P) at 10 min before the end of the operation. The incidence and severity of CRBD, postoperative pain, Ramsay scores, patient satisfaction, postoperative additional drugs and adverse effects were assessed at 5 min (T1), 1 h (T2), 6 h (T3) and 12 h (T4) after administration of the parecoxib by another observer who does not know research grouping situation.　Results　The incidence of CRBD in group P at T1, T2 and T3 was significantly lower than that in group C (89.3% vs 46.4%, 89.3% vs 35.7%, 67.9% vs 39.3%)(P<0.05), and the severity of CRBD in group P is lower than that of group C (P<0.05). Visual Analogue Scale(VAS) scores of group P at each observation time point were lower than those in group C(P<0.05). Ramsay scores, patient satisfaction, postoperative additional drugs and adverse reactions were no significant difference between the two groups (P>0.05).　Conclusions　Not only can a single intravenous injection of parecoxib 40 mg at the end of surgery effectively reduce the incidence and severity of postoperative CRBD in patients with TURBT, but also has certain analgesic effect without causing serious adverse reaction.